Dopamine Receptor, D2S, L, Human Control Peptide
Référence D9016-49-100ug
Conditionnement : 100ug
Marque : US Biological
Contactez votre distributeur local :
Téléphone : +1 850 650 7790
D9016-49Dopamine Receptor, D2S, L, Human Control Peptide
Specifications
GradeHighly Purified
ApplicationsE WB
Shipping TempBlue Ice
Storage Temp-20°C
Dopamine D2 receptor is known to exist in the short (D2S) and the long (D2L)forms that are encoded by splice variants of a single gene and differ only by the presence of an additional 29 amino acid in the intracellular, cytoplasmic loop 3 (1). D2L receptor is a 446 aa, G-protein coupled, and transmembrane receptor protein. A 19aa Peptide sequence within the N-terminal extracellular domain of human D2R.
Applications
Source: Human synthetic peptide|Purity: Highly purified|Concentration: 1mg/ml|Form: Supplied as a liquid in PBS, pH 7.2, 0.1% sodium azide|Specificity: The 19 AA human peptide is specific for D2R. No significant sequence homology is seen with other dopamine receptors (D1 and D3-D5). 100% homologous with rat and 84% with bovine D2R. Antibody crossreactivity with D2 receptors from various species is not known. Control peptide, because of its low mol size (<3kD), is not recommended for Western||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Form
Supplied as a liquid in PBS, pH 7.2, 0.09% sodium azide
Purity
Highly purified
Specificity
The 19 AA human peptide is specific for D2R. No significant sequence homology is seen with other dopamine receptors (D1 and D3-D5). 100% homologous with rat and 84% with bovine D2R. Antibody crossreactivity with D2 receptors from various species is not known. Control peptide, because of its low mol size (<3kD), is not recommended for Western
References
1. Dal Toso et (1989) EMBO J 8, 4025; Grandy DK et (1989) PNAS 86, 9762; Monsama FJ et al (1990) Nature 342, 926; Giros B et (1989) Nature 342, 923|2. Boundy, VA et al (1993) Mol Pharmacol. 43, 666-676|3. Sakata, M et al (1992) Brain Res. 575, 309-314; Farooqui, SM (1991) J Neurochem. 57, 1363-1369; Farooqui, SM et al (1992) BBRC 184, 661-667; Brock, J et al (1992) Brain Res. (1992) 578, 244-250; Farooqui, SM et al (1992) Life. Sci. 51, 1509-1516|4. Ogawa N (1995) Acta Med. Okayama 49, 1-11.